Cellular and virological mechanisms of HBV drug resistance
- 1 February 2006
- journal article
- review article
- Published by Elsevier in Journal of Hepatology
- Vol. 44 (2) , 422-431
- https://doi.org/10.1016/j.jhep.2005.11.036
Abstract
No abstract availableThis publication has 98 references indexed in Scilit:
- Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensationJournal of Hepatology, 2005
- 523 Effect of ALT flares on efficacy and safety of peginterferon α-2a (40 kDa) (PEGASYS®), peginterferon α-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (CHB)Journal of Hepatology, 2005
- 36 Incidence and predictors of emergence of adefovir resistant HBV during four years of adefovir dipivoxil (ADV) therapy for patients with chronic hepatitis B (CHB)Journal of Hepatology, 2005
- Persistence of cccDNA during the natural history of chronic hepatitis B and decline during adefovir dipivoxil therapy1 ☆Gastroenterology, 2004
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997
- A Preliminary Trial of Lamivudine for Chronic Hepatitis B InfectionNew England Journal of Medicine, 1995
- Hepatic purine and pyrimidine metabolism: implications for antiviral chemotherapy of viral hepatitisLiver International, 1995
- Adenine Arabinoside 5′–Monophosphate Treatment of Chronic Type B HepatitisHepatology, 1982
- Antiviral Treatment of Chronic Hepatitis B Virus Infection. I. Changes in Viral Markers with Interferon Combined with Adenine ArabinosideThe Journal of Infectious Diseases, 1981